health care outcomes? JAMA 1999 ; 282 : 867 – 874 . 23. Allard P Maunsell E Labbe J Dorval M . Educational interventions to improve cancer pain control: a systematic review . J Palliat Med 2001 ; 4 : 191 – 203 . 24. Ferris FD
Search Results
Tami Borneman, Barbara F. Piper, Virginia Chih-Yi Sun, Marianna Koczywas, Gwen Uman, and Betty Ferrell
Alexandra K. Zaleta, Shauna McManus, Joanne S. Buzaglo, Eva Y. N. Yuen, Julie S. Olson, Melissa F. Miller, Karen Hurley, Lillie D. Shockney, Sara Goldberger, Mitch Golant, and Kevin Stein
Background: Despite growing recognition that patient preferences and values should inform cancer care, patients’ views continue to be under-represented. We developed a quantitative tool, Valued Outcomes in the Cancer Experience (VOICE), to measure
Nila Alsheik, Zhaohui Su, Anna Lafontant, Gregory Donadio, Kathleen Troeger, Scott Pohlman, Melinda Talley, Vandana Menon, and Emily Conant
describe characteristics and outcomes of women who had only one screening mammogram versus those who had annual or biennial screens. Methods: A cloud-based big data platform is being used to integrate and transform data from electronic medical records
Zhubin J. Gahvari, Michael Lasarev, Jens C. Eickhoff, Aric C. Hall, Peiman Hematti, Mark B. Juckett, Vaishalee P. Kenkre, and Natalie S. Callander
obesity and transplant outcomes in MM patients in the era of modern therapy, routine post-transplant maintenance, and genetic-based risk stratification. Methods: We retrospectively reviewed consecutive patients undergoing autoPBSCT for MM at our
Cynthia Z. Qi, Min Huang, Amin Haiderali, Jipan Xie, Zheng-Yi Zhou, Eric Q. Wu, and Peter Fasching
long-term survival outcomes among patients with general BC and certain subtypes including triple negative BC (TNBC). To update and extend the evidence to assess the association of pCR and survival outcomes in TNBC, this study reviewed and summarized
Andrea Feldstain, Barry D. Bultz, Janet de Groot, Amane Abdul-Razzak, Leonie Herx, Lyle Galloway, Srini Chary, and Aynharan Sinnarajah
validated 12 – 15 ; however, it is considered a screening measure and not intended or appropriate for diagnostic purposes. Results in this study focus on outcomes regarding pain, fatigue, depression, anxiety, and well-being. Canadian Problem Checklist
Min Huang, Joyce O’Shaughnessy, Jing Zhao, Amin Haiderali, Javier Cortes, Scott Ramsey, Andrew Briggs, Vassiliki Karantza, Gursel Aktan, Cynthia Z. Qi, Chenyang Gu, Jipan Xie, Muhan Yuan, John Cook, Michael Untch, Peter Schmid, and Peter A. Fasching
These entities stipulate 2 criteria to establish surrogacy: (1) good correlation between the surrogate endpoint and the final outcome (individual-level association) and (2) good correlation between the treatment effect on the surrogate endpoint and the
Margaret M. Kozak, Clare E. Jacobson, Rie von Eyben, Erqi L. Pollom, Melinda Telli, and Kathleen C. Horst
, patients who still had residual disease in the breast did not have better outcomes compared with those who remained LN-positive. Cumulative incidence of LF, RF, and DF at 10 years by response to NAC is depicted in Table 2 , with corresponding cumulative
Narhari Timilshina, Antonio Finelli, George Tomlinson, Beate Sander, and Shabbir M.H. Alibhai
– 7 The foundation for quality assessment is based on the structure-process-outcomes paradigm by Donabedian. 8 – 11 The first quality indicators (QIs) for PC were developed more than a decade ago by investigators at RAND 12 – 16 and have
Zachary Veitch, Omar F. Khan, Derek Tilley, Domen Ribnikar, Xanthoula Kostaras, Karen King, Patricia Tang, and Sasha Lupichuk
-targeted therapies, such as trastuzumab. 3 – 5 However, outcomes for patients with HER2+ breast cancer treated outside of clinical trials are limited. 6 , 7 In small, node-negative, HER2+ tumors, the benefit of adding trastuzumab to adjuvant chemotherapy
